Syntis Bio: Funding, Investors & Team (Oct 2026)
Syntis Bio is a company focused on developing advanced oral therapies for obesity, diabetes, and rare diseases in the late stages of preclinical development. Their innovative drug formulations target specific tissues to improve bioavailability, providing more effective and readily accessible solutions for a wide range of health conditions. By utilizing the unique biology of the small intestine, Syntis Bio is at the forefront of developing therapies that offer sustainable solutions for various health issues, from rare disorders to common diseases. Their pipeline includes oral therapies designed to specifically target the small intestine, which plays a crucial role in metabolic control, digestion, and drug absorption.
Syntis Bio has raised $33.0M across 1 funding round on record, the most recent a Series A of $33.0M announced in Jul 2025.
That round is above the $4.9M median round size for Health Care companies tracked on FundedIQ over the last two years.
Syntis Bio Company Profile and Key Stats
Latest funding round on record: Jul 2025.
Syntis Bio Funding Rounds
Syntis Bio Founders and Leadership Team
Contact details for the Syntis Bio team: 1 of 1 has an email address on file.
Start 14-day free trial →Syntis Bio Funding Compared to Other Health Care Startups
Syntis Bio's latest round of $33.0M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Syntis Bio in Health Care and Boston
Companies Similar to Syntis Bio
Using technology and the best professionals, Wally, a membership-based dental care service, offers proactive,…
PreciseDx is a unique Cancer Risk Stratification company that offers personalized risk information by…
General Medicine provides a convenient and straightforward way to access top-quality healthcare services with…
Forty million men in the US and over 500 million worldwide suffer from urinary obstruction related to benign…
SedMed provides medical devices that support safer toileting transfers and help prevent falls for individuals…
Aptatek is developing cutting edge technologies for portable disease management devices that will improve…
Flow Medical offers multi-function catheters to aid in the diagnosis and treatment of venous thromboembolic…
Light Wave Dental Management offers management services for high-quality dental offices in Virginia.…
For health care systems and payers focused on improving maternal outcomes and health equity, our product is a…
Tempo Therapeutics creates materials that are designed for regenerative medicine, with a focus on being…
Vibronix was established by Dr. Ji-Xin Cheng and Dr. Pu Wang at Purdue University with the goal of offering…
People with chronic diseases can live their best lives thanks to Vheda Health. We concentrate on three areas…
Syntis Bio Funding FAQs
What does Syntis Bio do?
Syntis Bio is a company focused on developing advanced oral therapies for obesity, diabetes, and rare diseases in the late stages of preclinical development. Their innovative drug formulations target specific tissues to improve bioavailability, providing more effective and readily accessible solutions for a wide range of health conditions. By utilizing the unique biology of the small intestine, Syntis Bio is at the forefront of developing therapies that offer sustainable solutions for various health issues, from rare disorders to common diseases. Their pipeline includes oral therapies designed to specifically target the small intestine, which plays a crucial role in metabolic control, digestion, and drug absorption.
How much funding has Syntis Bio raised?
Syntis Bio has raised $33.0M across 1 round on record. The most recent is a Series A of $33.0M announced in Jul 2025.
When did Syntis Bio last raise funding?
Syntis Bio's most recent funding round on record is a Series A of $33.0M, announced in Jul 2025.
Who founded Syntis Bio?
FundedIQ lists Rahul Dhanda (Founder) at Syntis Bio.
Where is Syntis Bio headquartered?
Syntis Bio is based in Boston, Massachusetts, United States.
How many employees does Syntis Bio have?
Syntis Bio is in the 11-50 employee band.
How does Syntis Bio's funding compare to other Health Care startups?
Syntis Bio's latest round of $33.0M is above the $4.9M median round size for Health Care companies on FundedIQ across 3,659 tracked companies over the last two years.
About FundedIQ's Syntis Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Syntis Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.